A multicenter surveillance of antimicrobial resistance on Stenotrophomonas maltophilia in Taiwan

Journal of Microbiology, Immunology and Infection

Volumn 45, Issue 2, 2012, Pages 120-126

  Wu, Hsiu ^a   Wang, Jen Tay ^a,b   Shiau, Yih Ru ^b   Wang, Hui Yin ^b   Yang Lauderdale, Tsai Ling ^b   Chang, Shan Chwen ^a,c  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Antimicrobial resistance; Minimal inhibitory concentration; Stenotrophomonas maltophilia; Surveillance; Surveillance of Antimicrobial Resistance (TSAR); Taiwan

Indexed keywords

CEFTAZIDIME; CHLORAMPHENICOL; COTRIMOXAZOLE; LEVOFLOXACIN; MINOCYCLINE; TIGECYCLINE; TIMENTIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; BROTH DILUTION; HOSPITAL; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PREVALENCE; RESPIRATORY SYSTEM; STENOTROPHOMONAS MALTOPHILIA; TAIWAN;

AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; PREVALENCE; STENOTROPHOMONAS MALTOPHILIA; TAIWAN;

EID: 84859878039     PISSN: 16841182     EISSN: 19959133     Source Type: Journal    
DOI: 10.1016/j.jmii.2011.09.028     Document Type: Article

References (30)

1. Hoefel D., Monis P., Grooby W., Andrews S., Saint C. Profiling bacterial survival through a water treatment process and subsequent distribution system. J Appl Microbiol 2005, 99:175-186.
2. Hauben L., Vauterin L., Moore E., Hoste B., Swings J. Genomic diversity of the genus Stenotrophomonas. Int J Syst Microbiol 1999, 49:1749-1760.
3. Whitby P., Carter K., Burns J., Royall J., LiPuma J., Stull T.L. Identification and detection of Stenotrophomonas maltophilia by rRNA-directed PCR. J Clin Microbiol 2000, 38:4305-4309.
4. Safdar A., Rolston K.V. Stenotrophomonas maltophilia: changing spectrum of a serious bacterial pathogen in patients with cancer. Clin Infect Dis 2007, 45:1602-1609.
5. Nseir S., Di Pompeo C., Brisson H., Dewavrin F., Tissier S., Diarra M., et al. Intensive care unit-acquired Stenotrophomonas maltophilia: incidence, risk factors, and outcome. Crit Care 2006, 10:R143.
6. Hanes S., Demirkan K., Tolley E., Boucher B., Croce M., Wood G., et al. Risk factors for late-onset nosocomial pneumonia caused by Stenotrophomonas maltophilia in critically ill trauma patients. Clin Infect Dis 2002, 35:228-235.
7. Trouillet J., Chastre J., Vuagnat A., Joly-Guillou M., Combaux D., Dombret M., et al. Ventilator-associated pneumonia caused by potentially drug-resistant bacteria. Am J Respir Crit Care Med 1998, 157:531-539.
8. Looney W., Narita M., Muhlemann K. Stenotrophomonas maltophilia: an emerging opportunist human pathogen. Lancet Infect Dis 2009, 9:312-323.
9. Tan C.K., Liaw S.J., Yu C.J., Teng L.J., Hsueh P.R. Extensively drug-resistant Stenotrophomonas maltophilia in a tertiary care hospital in Taiwan: microbiologic characteristics, clinical features, and outcomes. Diagn Microbiol Infect Dis 2008, 60:205-210.
10. Paez J.I., Tengan F.M., Barone A.A., Levin A.S., Costa S.F. Factors associated with mortality in patients with bloodstream infection and pneumonia due to Stenotrophomonas maltophilia. Eur J Clin Microbiol Infect Dis 2008, 27:901-906.
11. Paez J.I., Costa S.F. Risk factors associated with mortality of infections caused by Stenotrophomonas maltophilia: a systematic review. J Hosp Infect 2008, 70:101-108.
12. Senol E., DesJardin J., Stark P.C., Barefoot L., Snydman D.R. Attributable mortality of Stenotrophomonas maltophilia bacteremia. Clin Infect Dis 2002, 34:1653-1656.
13. Alonso A., Martinez J. Multiple antibiotic resistance in Stenotrophomonas maltophilia. Antimicrob Agents Chemother 1997, 41:1140-1142.
14. Vartivarian S., Anaissie E., Bodey G., Sprigg H., Rolston K.A. Changing pattern of susceptibility of Xanthomonas maltophilia to antimicrobial agents: implications for therapy. Antimicrob Agents Chemother 1994, 38:624-627.
15. Falagas M.E., Valkimadi P.E., Huang Y.T., Matthaiou D.K., Hsueh P.R. Therapeutic options for Stenotrophomonas maltophilia infections beyond co-trimoxazole: a systematic review. J Antimicrob Chemother 2008, 62:889-894.
16. Nicodemo A., Paez J. Antimicrobial therapy for Stenotrophomonas maltophilia infections. Eur J Clin Microbiol Infect Dis 2007, 26:229-237.
17. Farrell D.J., Sader H.S., Jones R.N. Antimicrobial susceptibilities of a worldwide collection of Stenotrophomonas maltophilia isolates tested against tigecycline and agents commonly used for S. maltophilia infections. Antimicrob Agents Chemother 2010, 54:2735-2737.
18. Toleman M., Bennett P., Bennett D., Jones R., Walsh T. Global emergence of trimethoprim/sulfamethoxazole resistance in Stenotrophomonas maltophilia mediated by acquisition of sul genes. Emerg Infect Dis 2007, 13:559-565.
19. Sader H., Jones R., Dowzicky M., Fritsche T. Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit. Diagn Microbiol Infect Dis 2005, 52:203-208.
20. Insa R., Cercenado E., Goyanes M., Morente A., Bouza E. In vitro activity of tigecycline against clinical isolates of Acinetobacter baumannii and Stenotrophomonas maltophilia. J Antimicrob Chemother 2007, 59:583-585.
21. Wu P.S., Lu C.Y., Chang L.Y., Hsueh P.R., Lee P.I., Chen J.M., et al. Stenotrophomonas maltophilia bacteremia in pediatric patients - a 10-year analysis. J Microbiol Immunol Infect 2006, 39:144-149.
22. Hsueh P.R., Chen W.H., Luh K.T. Relationships between antimicrobial use and antimicrobial resistance in Gram-negative bacteria causing nosocomial infections from 1991-2003 at a university hospital in Taiwan. Int J Antimicrob Agents 2005, 26:463-472.
23. Sheng W.H., Wang J.T., Chen Y.C., Chang S.C., Luh K.T. In vitro activity of moxifloxacin against common clinical bacterial isolates in Taiwan. J Microbiol Immunol Infect 2001, 34:178-184.
24. Chang S.C., Fang C.T., Chen Y.C., Hsueh P.R., Luh K.T., Hsieh W.C. In vitro activity of meropenem against common pathogenic bacteria isolated in Taiwan. Diagn Microbiol Infect Dis 1998, 32:273-279.
25. Lauderdale T., McDonald L., Shiau Y., Chen P., Wang H., Lai J., et al. The status of antimicrobial resistance in Taiwan among gram-negative pathogens: the Taiwan surveillance of antimicrobial resistance (TSAR) program, 2000. Diagn Microbiol Infect Dis 2004, 48:211-219.
26. Performance standards for antimicrobial susceptibility testing: twentieth informational supplement, M100-S20 2010, CLSI, Clinical and Laboratory Standards Institute, Wayne, PA.
27. European Committee on Antimicrobial Susceptibility Testing. Clinical Breakpoints. Accessed March 1, 2011. http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Disk_test_documents/EUCAST_breakpoints_v1.3_pdf.pdf.
28. Ba B.B., Feghali H., Arpin C., Saux M.C., Quentin C. Activities of ciprofloxacin and moxifloxacin against Stenotrophomonas maltophilia and emergence of resistant mutants in an in vitro pharmacokinetic-pharmacodynamic model. Antimicrob Agents Chemother 2004, 48:946-953.
29. Garrison M.W., Anderson D.E., Campbell D.M., Carroll K.C., Malone C.L., Anderson J.D., et al. Stenotrophomonas maltophilia: emergence of multidrug-resistant strains during therapy and in an in vitro pharmacodynamic chamber model. Antimicrob Agents Chemother 1996, 40:2859-2864.
30. Zervos M., Hershberger E., Nicolau D., Ritchie D., Blackner L., Coyle E., et al. Relationship between fluoroquinolone use and changes in susceptibility to fluoroquinolones of selected pathogens in 10 United States teaching hospitals, 1991-2000. Clin Infect Dis 2003, 37:1643-1648.